Lecanemab for Alzheimer Disease, Is It Worth It?
Neurol 102:e209265, Nelson,S.E. & Lopez,O.L., 2024
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Aducanumab: What About the Patient?
Ann Neurol 90:334-335, Petersen, R.C., 2021
Tumor Necrosis Factor-Alpha Inhibitors: Risk of Malignancy
UpToDate January, Stone, J.H., 2013
Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
Neurol 77:1061-1067,1033, Tan, I.L.,et al, 2011
PANDAS
www.medlink.com,Feb, Erfe,M.C.B., 2011
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
Stiff-Person Syndrome
The Neurologist 10:131-137, Murinson,B.B., 2004
Potassium Channel Antibody-Associated Encephalopathy: A Potentially Immunotherapy-Responsive Form of Limbic Encepahlitis
Brain 127:701-712, Vincent,A.,et al, 2004
Do NMDA Antagonists Prevent Neuronal Injury? Yes
ARch Neurol 49:418-420, Albers,G.W.,et al, 1992
Antiplatelet and Anticoagulant Agents for Secondary Prevention of Thromboembolic Events in People with Antiphospholipid Syndrome
Stroke 49:e41-e42, Bala, M.M.,et al, 2018
Trial of Decompressive Craniectomy for Traumatic Intracranial Hypertension
NEJM 375:1119-1130,1183, Hutchinson, P.J.,et al, 2016
Early Transfer of Patients with Stroke to Comprehensive Centers is Necessary
Stroke 45:3748-3749,3752, Sheth, K.N., 2014
Early Transfer of Patients with Stroke to Comprehensive Stroke Centers is not Necessary
Stroke 45:3750-3751,3752, Langhorne, P., 2014
Risk of Dementia and AD with Prior Exposure to NSAIDs in an Elderly Community-Based Cohort
Neurol 72:1899-1905,1884, Breitner,J.C.S.,et al, 2009
Natalizumab: A Double-Edged Sword?
Ann Neurol 66:262-263, DeAngelis,L., 2009
Assessment of Declofenac or Spinal Manipulative Therapy, Or Both, in Addition to Recommended First-Line Treatment for Acute Low Back Pain: A Randomised Controlled Trial
Lancet 370:1638-1643, Hancock,M.J., et al, 2007
What Went Wrong in the Natalizumab Trials?
Lancet 367:706-709, Langer-Gould,A.&Steinman,L., 2006
Management of Antiphospholipid Antibody Syndrome, A Systematic Review
JAMA 295:1050-1057, Lim,W.,et al, 2006
Expanding Indications for Statins in Cerebral Ischemia
Arch Neurol 62:67-72,23, Ovbiagele,B.,et al, 2005
Thrombosis of the Cerebral VEins and Sinuses
NEJM 352:1791-1798, Stam,J., 2005
Steroids Have No Role in Stroke Therapy
Stroke 35:229-231, Poungvarin,N.,et al, 2004
Steroids May Have a Role in Stroke Therapy
Stroke 35:228-229,230, Norris,J.W., 2004
Surgical Decompression of Patients with Large Middle Cerebral Artery Infarcts is Effective
Stroke 34:2304-2305,2307, Schwab,S.&Hacke,W., 2003
Surgical Decopression of Patients With Large Middle Cerebral Artery Infarcts is Effective:Not Proven
Stroke 34:2305-2306,2307, Brown,M.M., 2003
Measurement of Antibodies to Interferon Beta in Patients With Multiple Sclerosis
Arch Neurol 58:1299-1300,1301, Pachner,A.R., 2001
The Significance of Neutralizing Antibodies in Patients With Multiple Sclerosis Treated With Interferon Beta
Arch Neurol 58:1297-1298,1301, Rice,G., 2001
Eclampsia
NEJM 289:976, 1973; 290:344974., Jewett,J.F., 1974